C-type natriuretic peptide (CNP) effects in anterior pituitary cell lines: evidence for homologous desensitisation of CNP-stimulated cGMP accumulation in αT3–1 gonadotroph-derived cells

R C Fowkes, W Forrest-Owen and C A McArdle

Abstract

C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, has been found at its highest tissue concentrations in the anterior pituitary, where it is localised in gonadotrophs. Its specific guanylyl cyclase-containing receptor, GC-B, is also expressed on several anterior pituitary cell types, and CNP potently stimulates cGMP accumulation in rat pituitary cell cultures and pituitary cell lines. The mouse gonadotroph-derived αT3–1 cell line has been shown to express CNP as well as GC–B (but not GC–A) receptors, suggesting that CNP may well be an autocrine regulator of gonadotrophs. Comparing effects of three natriuretic peptides (atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and CNP) on cGMP accumulation in four pituitary cell lines (αT3–1, TrT–GF, ArT–20 and GH3) we find that CNP is most potent and effective in αT3–1 cells. In these cells, CNP-stimulated cGMP accumulation was found to desensitise during a 30 min exposure to CNP. Pretreatment with CNP for up to 6 h also caused a significant reduction in the ability of CNP to subsequently stimulate cGMP accumulation. This effect was receptor specific, because pretreatment with sodium nitroprusside (an activator of nitric oxide-sensitive guanylyl cyclase), or with ANP or BNP, did not cause desensitisation of CNP-stimulated cGMP accumulation. Protein kinase C activation with phorbol esters also inhibited CNP-stimulated cGMP accumulation and such inhibition was also seen in cells desensitised by pretreatment with CNP. Thus it appears that the endogenous GC–B receptors of αT3–1 cells are subject to both homologous and heterologous desensitisation, that the mechanisms underlying these forms of desensitisation are distinct, and that cGMP elevation alone is insufficient to desensitise GC–B receptors.

Introduction

The natriuretic peptides atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) act via their specific guanylyl cyclase-containing receptors to stimulate cGMP accumulation. ANP and BNP exert well-documented effects on haemodynamic and cardiovascular regulation (Samson 1992, Wilkins et al. 1993). Of the three peptides, CNP has the lesser role in these pathways, and the finding that its highest tissue concentration is in the anterior pituitary suggests that it may perform regulatory roles alternative to those described for ANP and BNP (Komatsu et al. 1991). In rats and mice, CNP is localised in luteinising hormone-positive cells of the anterior pituitary (McArdle et al. 1994b). Previous studies in αT3–1 cells have shown that gonadotrophin-releasing hormone (GnRH), an important regulator of gonadotrophs and an essential regulator of reproductive function, can inhibit CNP-stimulated cGMP accumulation (McArdle et al. 1995). However, CNP has recently been shown to inhibit GnRH-stimulated calcium mobilisation, suggesting that a reciprocal regulatory pathway exists between CNP and GnRH (Fowkes et al. 1999).

The majority of natriuretic peptide effects are exerted via their guanylyl cyclase receptors, namely GC–A and GC–B (Chang et al. 1989, Chinkers et al. 1989, Garbers 1989). These single transmembrane-region proteins contain intrinsic guanylyl cyclase, and share homology with the family of growth factor receptors, although they have not been shown to exert kinase activity (Chinkers et al. 1989, Drewett & Garbers 1994). ANP and BNP preferentially bind to and stimulate the GC–A receptor, whereas CNP is considerably more effective than ANP or BNP at activating the GC–B receptor (Suga et al. 1992). These receptors are expressed in almost all tissues of the body, and many anterior pituitary cell types are known to express one or both receptors (Gutkowska & Nemer 1989, Anand-Srivastava & Trachte 1993, Grandclément et al. 1995).
However, there is conflicting evidence, based on a number of studies, as to which natriuretic peptide GC receptor is predominant in anterior pituitary cells, due mostly to the diverse range of techniques utilised (Kurihara et al. 1987, Koch et al. 1988, Wilcox et al. 1991, Konrad et al. 1992, Talleric-Mellyk et al. 1992, McArdle et al. 1993, 1994a,b, Gilkes et al. 1994a, Shimekake et al. 1994, Grandclément et al. 1995, Langub et al. 1995, Guild & Cramb 1999).

Regulation of natriuretic peptide-stimulated cGMP accumulation has been studied over recent years (Potter & Garbers 1992, 1994, McArdle et al. 1993, Potter 1998). Previous studies, using cells transfected with either GC-A or GC-B receptors, have revealed that these receptors exist as phosphoproteins (predominantly serine/threonine residues) when inactive (Potter & Garbers 1994, Potter & Hunter 1998). Prolonged activation by the respective ligand (ANP or CNP) can cause dephosphorylation of these residues, resulting in homologous desensitisation of the transfected receptors (Potter & Garbers 1994, Potter 1998). In addition, activators of protein kinase C (PKC), such as 12-phorbol, 13-myristate acetate (PMA) and GnRH have been shown to inhibit natriuretic peptide-stimulated cGMP accumulation in a number of tissues, in a receptor-specific manner (McArdle et al. 1993, 1994a, Yeung et al. 1992, Gilkes et al. 1994a, Potter & Garbers 1994, Paulding & Sumners 1996). We have shown that the GC-B receptors of αT3-1 cells are subject to heterologous regulation (inhibition by GnRH and phorbol esters) (McArdle et al. 1994a) but homologous regulation of endogenous GC-B has not yet been reported.

In addition to CNP, gonadotrophs also express the enzyme responsible for the generation of nitric oxide (NO), NO synthase (NOS) (Ceccatelli et al. 1993). NO has also been shown to activate the cGMP signalling pathway, by interacting with the ligand-binding domain of intracellular (soluble) guanylyl cyclase receptors (Drewett & Garbers 1994, Wedel & Garbers 1998). As gonadotrophs are known to express NOS, soluble guanylyl cyclase, CNP and GC-B receptors, this predisposes them to be important regulators of cGMP signalling within the anterior pituitary (Ceccatelli et al. 1993, McArdle et al. 1993, Garrel et al. 1998).

By comparing responses to three natriuretic peptides in four pituitary cell lines, we provide evidence here that GC-B receptors in gonadotrophs are the major targets for natriuretic peptide action in the anterior pituitary. We also show that these receptors undergo homologous as well as heterologous desensitisation, and that these effects are additive, implying that distinct mechanisms underlie these two forms of modulation.

Materials and Methods

Materials

Culture medium and supplements were from Gibco BRL (Paisley, Strathclyde, UK) and rat ANP (residues 99–126), rat BNP (32 residues) and porcine CNP (22 residues) were purchased from Peninsula Laboratories (Merseyside, UK). Sodium nitroprusside (SNP), an activator of the NO-sensitive soluble guanylyl cyclase, isobutyl methylxanthine (IBMX), PMA and synthetic CNP were all purchased from Sigma Chemical Co. (Poole, Dorset, UK). αT3-1 cells (Windle et al. 1990) were kindly provided by Prof. P Mellon (University of California San Diego, Department of Reproductive Medicine, La Jolla, CA, USA). All other reagents were from standard commercial suppliers.

Cell culture

αT3–1, TrT–GF (Inoue et al. 1992) and AtT–20 cells were maintained in Dulbecco’s modified Eagle’s medium with 2 mM glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, 10% (v/v) foetal calf serum (FCS) and 2.5% (v/v) horse serum (HS) (culture medium) under a water-saturated atmosphere containing 5% (v/v) CO2 in air at 37 °C. GH3 cells were cultured in similar medium, but supplemented with 5% FCS, 5% HS. Cells were cultured in T25 and T75 flasks (Nunc, Life Technologies, Paisley, UK) and were passaged at 7 day intervals as described previously (McArdle et al. 1993, 1994a). In preparation for experiments, the cells were harvested by trypsinisation, then incubated in 24-well plates (Falcon, Life Technologies, Paisley, UK), or until they reached approximately 70% confluence. Variability was seen in the responsiveness of the cells from experiment to experiment. Therefore, normalisation was performed on data from the same cells from the same experimental day. The DNA content of cells was determined as required using a standard curve of calf thymus DNA, ranging from 0.39 to 100 µg/ml and 25 µl of 4 µg/ml bisbenzamidazole (Hoescht 33258, BDH, Poole, UK), according to the manufacturer’s instructions.

Natriuretic peptide stimulation of cGMP accumulation

Cells were washed before use in a physiological salt solution (PSS: 127 mM NaCl, 1.8 mM CaCl2, 5 mM KCl, 2 mM MgCl2, 0.5 mM NaH2PO4, 5 mM NaHCO3, 10 mM glucose, 0.1% (w/v) BSA, and 10 mM Hepes, at pH 7.4) at 37 °C. Any pretreatments were conducted in PSS without the non-specific phosphodiesterase inhibitor, IBMX. Before stimulation, pretreatments were removed and the cells were again washed with PSS at 37 °C. The cells were stimulated with 250 µl PSS containing 10−3 M IBMX and the indicated stimuli. The stimulations were terminated by the addition of 750 µl 100% ethanol at −20 °C. The plates were kept at −20 °C for at least 1 h before centrifugation at 250 g, at 4 °C for 10 min. The supernatants were collected, vacuum dried under heat (60 °C) and reconstituted with 500 µl assay buffer (Medium 199, 10 mM Hepes (pH 7.4), 0.05% (w/v)
sodium azide). These samples were stored at −20°C to await assay for cGMP content.

Iodination, purification and RIA of cGMP

Ethanol extracted cGMP was measured by RIA as described previously (McArdle et al. 1993). 125I-cGMP-tyrosylmethyl ester (TME) was prepared from cGMP-TME and [125I]NaI by the chloramine-T method (Hunter & Greenwood 1962), and purified by column gel filtration. The range of the standard curve was from 0–0.42 to 25 pmol/100 µl, and cGMP antisera, provided by Dr M Schumacher (Institute for Hormone and Fertility Research, University of Hamburg, Germany) was used at 1:480 000 final dilution. Bound 125I-cGMP was precipitated with 10% (w/v) PBS, containing 16% (w/v) PEG-6000, 0·1% (w/v) NaN3, 1% (v/v) normal rabbit serum and 1% (v/v) donkey anti-rabbit IgG (SAPU, Lanarkshire, UK). After a 5 min incubation, the tubes were centrifuged for 15 min at 500 g, at 4°C. The supernatants were decanted and the radiiodine in the resulting pellets was counted for 1 min in a Packard multiwell gamma counter. The inter-assay variation was approximately 8%.

Data presentation and statistical analysis

The figures show data from multiple experiments and are reported as the mean ± s.e.m. of n independent observations, performed in triplicate on different days. In some instances, data are reported as a percentage of control response values, as indicated in the figure legends. Statistical analysis was by ANOVA followed by Student’s t-test or Tukey’s multiple comparisons test, accepting P<0·05 as statistically significant. All data shown were analysed and plotted using GraphPad Prism 2·01 and 3·0 (GraphPad, San Diego, CA, USA).

Results

Comparison of natriuretic peptide action in pituitary cell lines

Previous studies have revealed that natriuretic peptides stimulate cGMP accumulation in αT3–1 (McArdle et al. 1993, 1994a), ArT–20 (Gilkes et al. 1994b) and GH3 cells (Hartt et al. 1995, McArdle et al. 1993), but there has been no internally controlled comparative study to establish the effectiveness of ANP, BNP and CNP in these cell lines. We have previously found CNP to stimulate cGMP accumulation in αT3–1 cells with an approximate EC50 value of 5 × 10–8 M (McArdle et al. 1993, 1994a). Our preliminary studies investigating natriuretic peptide and SNP-stimulated cGMP accumulation in pituitary cell lines revealed that CNP was the most effective stimulator of cGMP accumulation in αT3–1, TtT-GF and ArT–20 cells, and was as equally effective as ANP in GH3 cells (data not shown). SNP was only effective in αT3–1 and ArT–20 cells (Table 1). A comparison of the effectiveness of CNP and SNP-stimulated cGMP accumulation in the four cell lines was facilitated by normalising cGMP accumulation per microgram DNA. This revealed that αT3–1 cells produced significantly more cGMP in response to 10–6 M CNP and 10–7 M SNP than any other cell line (P<0·01 and P<0·001 respectively) (Table 1).

Homologous desensitisation of CNP-stimulated cGMP accumulation

To establish whether CNP-stimulated cGMP accumulation was subject to homologous desensitisation, αT3–1 cells were subjected to time-course treatments with 10–7 M CNP in the presence of 10–3 M IBMX. As shown (Fig. 1), the initial rate of cGMP accumulation was not maintained and the cGMP level reached a plateau after 10 min.

Effect of CNP pretreatment on CNP-stimulated cGMP accumulation

To establish whether prolonged activation of the GC-B receptor resulted in an attenuated response to subsequent stimulation with CNP, αT3–1 cells were pretreated for up to 6 h with PSS containing 0 or 10–7 M CNP. Following a thorough wash with PSS, the cells were stimulated for 15 min with PSS containing 10–7 M CNP, in the presence of IBMX (Fig. 2A). The CNP response in cells pretreated for 3 and 6 h was significantly reduced compared with non-pretreated cells (to 55·4 ± 8·3 and 42·8 ± 8·3%, P<0·05 and P<0·01 respectively). Having established that

Table 1 The magnitude of CNP- and SNP-stimulated cGMP accumulation varies between the anterior pituitary-derived cell lines. Responses of cells to 10–6 M CNP and 10–7 M SNP in the presence of 10–3 M IBMX for 15 min (pmol/µg DNA, means ± s.e.m, n=3)

<table>
<thead>
<tr>
<th>Cell line</th>
<th>αT3-1</th>
<th>GH3</th>
<th>TtT-GF</th>
<th>ArT-20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response to 10–6 M CNP</td>
<td>9·2 ± 1·9**</td>
<td>2·6 ± 0·4</td>
<td>1·1 ± 0·1</td>
<td>0·8 ± 0·1</td>
</tr>
<tr>
<td>Response to 10–7 M SNP</td>
<td>5·6 ± 0·9***</td>
<td>0·02 ± 0·004</td>
<td>0·02 ± 0·009</td>
<td>1·2 ± 0·1</td>
</tr>
</tbody>
</table>

**P<0·01; ***P<0·001 compared with the other pituitary cell lines.
CNP pretreatment for up to 6 h could reduce the responsiveness of αT3–1 cells to subsequent stimulation by CNP, an experiment was conducted to determine whether this effect was concentration dependent. αT3–1 cells were pretreated for 6 h with PSS containing 0 or 10⁻⁹ M to 10⁻⁶ M CNP, before being washed and stimulated for 15 min with PSS containing 10⁻⁷ M CNP, in the presence of IBMX (Fig. 2B). Pretreatment with 10⁻⁸ M, 10⁻⁷ M or 10⁻⁶ M CNP significantly reduced the response to subsequent CNP stimulation to 36.2 ± 13.7, 14.9 ± 5.6 and 20.4 ± 7.5% compared with non-pretreated cells (P<0.05, P<0.01 and P<0.01 respectively).

Receptor specificity of CNP-dependent homologous desensitisation

Previous studies have failed to detect any GC-A mRNA in αT3–1 cells, suggesting that all natriuretic peptide-stimulated cGMP accumulation occurs via the GC-B receptor (McArdle et al. 1994a). To test the receptor specificity of homologous desensitisation, αT3–1 cells were pretreated for 6 h with PSS containing 0, 10⁻⁷ M ANP, BNP or CNP, or with 10⁻³ M SNP, before subsequent stimulation with PSS containing 10⁻⁷ M CNP for 15 min, in the presence of IBMX. ANP, BNP or SNP pretreatments failed to alter subsequent CNP-stimulated cGMP accumulation, but CNP pretreatment caused the expected attenuation in the cGMP response to subsequent CNP stimulation to 30.9 ± 3.9% of control (P<0.01, Fig. 3A). By means of comparison, αT3–1 cells were again pretreated with ANP, BNP, CNP or SNP for 6 h but were then stimulated with 10⁻³ M SNP for 15 min. The natriuretic peptides failed to alter the response to SNP, but SNP-pretreated cells showed a significantly inhibited response to subsequent stimulation with SNP to 22.7 ± 2.1% of control (P<0.05, Fig. 3B).

Effect of CNP pretreatment on GC-B concentration responsiveness to CNP

To further investigate the apparent homologous desensitisation of CNP action in pretreated cells, a concentration–response curve to CNP was examined in cells that were
pretreated with 0 or $10^{-7}$ M CNP for 6 h (Fig. 4). In both control and pretreated cells, subsequent stimulation with $10^{-8}$, $10^{-7}$ and $10^{-6}$ M CNP significantly stimulated cGMP accumulation above basal values. However, pretreatment caused a significant reduction in the responses to subsequent stimulation with $10^{-8}$, $10^{-7}$ and $10^{-6}$ M CNP compared with similar responses in control cells ($P<0.01$ and $P<0.001$).

Comparison of homologous and heterologous desensitisation of CNP-stimulated cGMP accumulation

Heterologous inhibition of CNP action by activators of PKC activity has previously been reported in αT3–1 cells (McArdle et al. 1993, 1994a). To establish whether heterologous desensitisation of CNP action in αT3–1 cells could occur even in cells desensitised to CNP by pretreatment, αT3–1 cells were pretreated with either 0 or $10^{-7}$ M CNP for 6 h prior to stimulation with $10^{-6}$ M CNP concentrations for 15 min in the absence or presence of $10^{-7}$ M PMA. CNP pretreatment significantly inhibited the cGMP response to $41.7 \pm 6.7\%$ of control, but the presence of PMA further reduced CNP-stimulated cGMP accumulation in pretreated cells to $16.4 \pm 6.6$ and $12.6 \pm 5.1\%$ of control (Fig. 5A). None of the treatments significantly affected SNP-stimulated cGMP accumulation (Fig. 5B).

Discussion

Many pituitary cell types have been shown to express natriuretic peptide receptors and to respond to natriuretic peptides, to stimulate cGMP accumulation (McArdle et al. 1993, 1994a, Gilkes et al. 1994b, Grandclément et al. 1995,
 Regulation of CNP action in gonadotrophs

Figure 5 Homologous and heterologous desensitisation of CNP-stimulated cGMP accumulation occur concurrently in αT3–1 cells. (A) αT3–1 cells were pretreated with PSS containing 0 or 10^{-7} M CNP for 6 h, then washed and stimulated with 10^{-6} M CNP and 0 or 10^{-7} M PMA (co-stimulation) in the presence of 10^{-3} M IBMX for 15 min. The cGMP response to CNP in pretreated cells was significantly reduced compared with control cells (**P<0.001, n=5). PMA-co-stimulated cells showed even greater inhibition than CNP-pretreated cells (*P<0.05, **P<0.01). However, there was no significant difference between PMA-co-stimulated control or CNP-pretreated cells (P>0.5). The data shown are expressed as a percentage (± S.E.M.) of the internal control response to 10^{-6} M CNP (which ranged from approximately 70 to 215 pmol/ml).

(B) αT3–1 cells were pretreated with PSS containing 0 or 10^{-7} M CNP for 6 h, then washed and stimulated with 10^{-3} M SNP and 0 or 10^{-7} M PMA (co-stimulation) in the presence of 10^{-3} M IBMX for 15 min. Neither CNP pretreatment nor PMA co-stimulation significantly affected SNP-stimulated cGMP accumulation (P>0.5, n=5). The data shown are expressed as a percentage (± S.E.M.) of the internal control response to 10^{-3} M SNP (which ranged from approximately 30 to 75 pmol/ml).

Using four pituitary cell lines, we have determined the effectiveness of the natriuretic peptides at stimulating cGMP accumulation in each cell type. We established that CNP is the most potent natriuretic peptide in αT3–1, TtT-GF and ArT–20 cells, and is as equipotent as ANP in GH_{3} cells. Furthermore, the concentration of cGMP produced in response to CNP in αT3–1 cells was significantly greater than that seen in the other pituitary cell lines. Although the current data were derived from anterior pituitary cell lines, they complement previous studies which showed that CNP-stimulated cGMP accumulation in heterogeneous populations of rat pituitary cells was inhibited by greater than 50% following gonadotroph ablation (McArdle et al. 1994b). Taken together, these data support the hypothesis that gonadotrophs are the major target cell type for CNP action in the pituitary.

As well as assessing the potency of the natriuretic peptides in these pituitary cell lines, the ability of the NO donor, SNP, to stimulate cGMP accumulation in these cells was also investigated. NO can activate the intracellular (soluble) guanylyl cyclases to produce cGMP, a mechanism by which NO exerts many of its biological effects (Drewett & Garbers 1994, Wedel & Garbers 1998). However, only αT3–1 and ArT–20 cells responded to SNP, suggesting that these cells express functional soluble guanylyl cyclase receptors. The finding that TtT-GF cells did not respond to SNP is interesting, as folliculo-stellate cells, along with gonadotrophs, are thought to be the only anterior pituitary cell types to express NOS, and therefore NO (Ceccatelli et al. 1993). The inability of an NO donor to stimulate cGMP in these cells suggests that the NO produced in folliculo-stellate cells acts as a paracrine regulator of other pituitary cell types or that NO autocrine effects on folliculo-stellate cells are mediated via target proteins other than GC.

The major aim of the current study was to establish whether endogenously expressed GC-B receptors in αT3–1 cells are subject to homologous as well as heterologous desensitisation, as desensitisation can be dependent upon the context of receptor expression and receptor number. Considerable evidence exists for the homologous and heterologous desensitisation of the ANP-specific, GC-A receptor (Potter & Garbers 1992, 1994). However, until recently, regulation of CNP action and particularly of the GC-B receptor had not been widely understood. Potter & Hunter (1998) showed that in HEK293 cells transfected with GC-B receptor cDNA, the receptor exists in a phosphorylated state when unstimulated, in common with the GC-A receptor (Potter & Garbers 1992, 1994). Following prolonged stimulation with CNP, GC-B receptors overexpressed in NIH3T3 cells appear to undergo homologous desensitisation due to the dephosphorylation of specific serine/threonine residues, which is manifested by a reduced ability of CNP to stimulate cGMP accumulation (Potter 1998).

To further establish how CNP action might be regulated in αT3–1 cells, we pretreated αT3–1 cells with CNP and other stimulators of cGMP accumulation in these cells, for up to 6 h to determine the effect on cGMP generation following subsequent treatment with CNP in the presence of the phosphodiesterase inhibitor, IBMX. We have shown that CNP-stimulated cGMP accumulation,
mediated via endogenously expressed GC-B receptors in \( \alpha T3-1 \) cells, is subject to both chronic and acute homologous desensitisation following prolonged exposure to CNP, and that elevated cGMP concentrations are not the sole regulatory mechanism for these observations.

\( \alpha T3-1 \) cells stimulated for up to 30 min with CNP failed to maintain the initial rate of cGMP accumulation, even in the presence of a maximally effective dose of IBMX. This suggests that the GC-B receptor undergoes rapid homologous desensitisation within the first 10–30 min of activation by CNP. This decline in the rate of cGMP formation is unlikely to be caused by an increase in phosphodiesterase activity as neither ANP, BNP nor SNP affected CNP-stimulated cGMP accumulation, although these treatments can stimulate cGMP accumulation to varying degrees in \( \alpha T3-1 \) cells (McArdle et al. 1993, 1994a). Furthermore, activators of cAMP accumulation in \( \alpha T3-1 \) cells such as pituitary adenylate cyclase-activating polypeptide or forskolin, also fail to affect CNP-stimulated cGMP accumulation, yet these treatments would be expected to elevate cyclic nucleotide phosphodiesterase activity in these cells (McArdle et al. 1993, R C Fowkes & C A McArdle, unpublished observations).

The decline in the rate of cGMP accumulation after 10 min is in agreement with the recently published data on the dephosphorylation and desensitisation of overexpressed GC-B receptors by CNP (Potter 1998) in NIH3T3 cells. However, Potter & Garbers (1994) have shown that prolonged treatment (>1 h) with ANP leads to loss of transfected GC-A receptor protein. Therefore, the current observations in \( \alpha T3-1 \) cells pretreated for 6 h are potentially due to a combination of receptor desensitisation and receptor loss. The mechanisms for the currently observed effects on GC-B receptors are not known at present. However, what is intriguing about the homologous desensitisation of the GC-B receptor by CNP in \( \alpha T3-1 \) cells is that the phenomenon cannot be explained purely by the prolonged accumulation of cGMP in these cells. Neither SNP, ANP nor BNP pretreatments significantly affected CNP-stimulated cGMP accumulation (Fig. 3A), yet SNP significantly stimulates cGMP accumulation in \( \alpha T3-1 \) cells (see Table 1), and ANP and BNP can also cause significant elevations in cGMP accumulation in these cells, albeit at micromolar concentrations (McArdle et al. 1993, 1994a). Thus cGMP elevation alone is insufficient to cause GC-B desensitisation, although it is possible that desensitisation requires elevation of cGMP to activate proteins that act specifically on the active conformation of the receptor. This has been suggested to be the case for the GC-A receptor, where the presence of ANP at the GC-A receptor is needed in order for the receptor to undergo desensitisation (Potter & Garbers 1994).

In all experiments, the NO donor SNP was used as a comparative treatment. It was interesting to note that pretreatment of \( \alpha T3-1 \) cells with SNP caused marked homologous down-regulation of cGMP accumulation in response to subsequent stimulation with SNP. In fact, the inhibition of the cGMP response in these pretreated cells was even more pronounced than the parallel observation seen in CNP-pretreated cells in response to CNP (~15% of control compared with ~30% of control respectively). Desensitisation of soluble guanylyl cyclase, or effects similar to such a phenomenon, have been observed in other cells (Zhang et al. 1993, Ujie et al. 1994). However, this study is the first to report such regulation in anterior pituitary-derived cells. Furthermore, these previous studies showed that the desensitisation of the soluble guanylyl cyclase by SNP could be mimicked by treatment with ANP or cell-permeable cGMP analogues (Zhang et al. 1993), and in vascular smooth muscle cells SNP pretreatment significantly increased subsequent ANP-stimulated cGMP accumulation (Ujie et al. 1994). This is in contrast with the results of the current study in which none of the natriuretic peptides were able to inhibit subsequent SNP-stimulated cGMP accumulation, suggesting that distinct mechanisms for the desensitisation of soluble guanylyl cyclases exist in \( \alpha T3-1 \) cells.

Previous studies have shown that activators of PKC (e.g. PMA, GnRH) are able to attenuate CNP-stimulated cGMP accumulation (McArdle et al. 1993, 1994a, Yeung et al. 1992) without affecting the NO-sensitive guanylyl cyclase (McArdle et al. 1993, 1994a), suggesting that the PKC effect is receptor specific. A similar phenomenon has been observed in cells expressing the ANP-specific GC-A receptor, where PKC activity leads to the dephosphorylation of the GC-A receptor and desensitises it to subsequent stimulation by ANP (Potter & Garbers 1994). In the current study we have compared the extent to which CNP pretreatment and PMA co-stimulation cause homologous and heterologous desensitisation of CNP-stimulated cGMP accumulation, reasoning that an additive effect would suggest distinct mechanisms. The major finding from these experiments was that PMA was able to significantly reduce CNP-stimulated cGMP accumulation even in CNP-pretreated cells (see Fig. 5A). In contrast, neither pretreatment with CNP nor co-stimulation with PMA was able to affect SNP-stimulated cGMP accumulation (Fig. 5B). This suggests that the mechanisms responsible for CNP-dependent and PKC-dependent desensitisation of GC-B receptors are distinct, although they may both involve receptor dephosphorylation (Potter & Garbers 1994).

In summary we have shown that CNP is a more efficient stimulus for cGMP accumulation in \( \alpha T3-1 \) cells than in GH3, TrT-GF or ArT-20 cells. Taken together with the fact that gonadotrophs express CNP, NOS, GC-B and soluble GC (Ceccatelli et al. 1993, McArdle et al. 1993, 1994a,b) these data support the notion that cGMP levels in gonadotrophs are controlled by autocrine and/or paracrine regulation of both soluble and particulate GCs. We also show, for the first time, that cGMP accumulation mediated by endogenous GC-B receptors...
can be subject to both homologous and heterologous desensitisation and that the mechanisms underlying these forms of desensitisation are likely to differ. Nevertheless, the physiological role(s) played by cGMP in gonadotrophs are essentially unknown and the relevance of these novel forms of regulation remains equally enigmatic.

Acknowledgements

The authors wish to thank Prof. P Mellon for the kind gift of the αT3–1 cells, Dr M Schumacher for provision of the cGMP antisera for use in the cGMP RIA, and Mr B Williams for practical assistance. This work was generously funded by a studentship awarded to R C F by the Needham Cooper Fellowship. Finally, R C F acknowledges the support and assistance given by Prof. S L Lightman, and thanks Prof. J M Burrin and Prof. A J Clarke for their constructive comments during the preparation of this manuscript.

References


Drewett JG & Garbers DL 1994 The family of guanylyl cyclase receptors and their ligands. Endocrine Reviews 15 135–162.


Gilkes AF, Guild SB & Cramb G 1994a Phorbol ester activation of protein kinase C inhibits CNP-stimulated cGMP production in the mouse anterior pituitary hormone cell line. Biochemistry and Biophysical Research Communications 204 1318–1324.


Hartt DJ, Ogwara T, Ho AK & Chik CL 1995 Cyclic GMP stimulated growth hormone release in rat anterior pituitary cells. Biochemical and Biophysical Research Communications 214 918–926.


Received 10 January 2000
Accepted 14 March 2000